icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
March 4-7, 2019
Back grey_arrow_rt.gif
Once-Daily Doravirine in HIV-1-Infected,
Antiretroviral-Naive Adults: An Integrated Efficacy Analysis
  Reported by Jules Levin
CROI 2019 March 4-7 Seattle
Chloe Orkin,1 Jean-Michel Molina,2 Johan Lombaard,3 Edwin DeJesus,4 Anthony Rodgers,5 Sushma Kumar,5 Elizabeth Martin,5 George J. Hanna,5 Carey Hwang5
1Queen Mary University, London, United Kingdom; 2Department of Infectious Diseases, Saint-Louis Hospital, Paris, France; 3Josha Research, Bloemfontein, South Africa; 4Orlando Immunology Center, Orlando, FL, USA; 5Merck & Co., Inc., Kenilworth, NJ, USA









1. Delstrigo [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2018.
2. Pifeltro [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2018.
3. Lai MT, Feng M, Falgueyret JP, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652-1663.
4. Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai MT. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59(1):590-598.
5. Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20(4):397-405.
6. Khalilieh S, Yee KL, Sanchez RI, et al. Results of a doravirine-atorvastatin drug-drug interaction study. Antimicrob Agents Chemother. 2017;61(2).
7. Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig. 2017;37(6):571-579.
8. Khalilieh S, Yee KL, Sanchez RI, et al. Co-administration of doravirine with an aluminum/magnesium-containing antacid or pantoprazole, a proton-pump inhibitor, does not have a clinically meaningful effect on doravirine pharmacokinetics. Poster presented at: 9th International AIDS Society (IAS) Conference on HIV Science; July 23-26, 2017; Paris, France.
9. Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211-e220.
10. Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2018.
11. Thompson M, Orkin C, Molina JM, et al. An integrated safety analysis comparing once-daily doravirine (DOR) to darunavir+ritonavir (DRV+r) and efavirenz (EFV) in HIV-1-infected, antiretroviral therapy (ARV)-naïve adults. Poster presented at: IDWeek; October 3-7, 2018; San Francisco, CA.